Deutsch English Français

Contact

EP1097167

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1097167

EP1097167 - NEUROTROPHIC GROWTH FACTOR [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 09.11.2018 Database last updated on 26.06.2024
Most recent event Tooltip	11.10.2019	Lapse of the patent in a contracting state New state(s): AT	published on 13.11.2019 [2019/46]
Applicant(s)	For all designated states Janssen Pharmaceutica NV Turnhoutseweg 30 2340 Beerse / BE
	[2018/50]
Former [2001/19]	For all designated states JANSSEN PHARMACEUTICA N.V. Turnhoutseweg 30 2340 Beerse / BE
Inventor(s)	01 / GEERTS, Hugo Alfonso Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse / BE
	02 / MASURE, Stefan, Leo, Jozef Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse / BE
	03 / MEERT, Theo Frans Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse / BE
	04 / CIK, Miroslav Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse / BE
	05 / VER DONCK, Luc, August, Laurentius Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse / BE
	[2018/50]
Former [2001/19]	01 / GEERTS, Hugo Alfonso Janssen Pharmaceutica N.V., Turnhoutseweg 30 B-2340 Beerse / BE
	02 / MASURE, Stefan, Leo, Jozef Janssen Pharmaceutica N.V., Turnhoutseweg 30 B-2340 Beerse / BE
	03 / MEERT, Theo Frans Janssen Pharmaceutica N.V., Turnhoutseweg 30 B-2340 Beerse / BE
	04 / CIK, Miroslav Janssen Pharmaceutica N.V., Turnhoutseweg 30 B-2340 Beerse / BE
	05 / VER DONCK, Luc, August, Laurentius Janssen Pharmaceutica N.V., Turnhoutseweg 30 B-2340 Beerse / BE
Representative(s)	Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB
	[N/P]
Former [2018/50]	Boult Wade Tennant LLP Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Former [2014/02]	Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Former [2010/42]	Baldock, Sharon Claire Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Former [2008/28]	Blance, Stephen John Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT / GB
Application number, filing date	99938261.7	14.07.1999
	[2001/19]
	WO1999EP05031
Priority number, date	GB19980015283	14.07.1998 Original published format: GB 9815283
	US19990248772	12.02.1999 Original published format: US 248772
	US19990327668	08.06.1999 Original published format: US 327668
	[2001/19]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0004050
	Date:	27.01.2000
	Language:	EN
	[2000/04]
	Type:	A2 Application without search report
	No.:	EP1097167
	Date:	09.05.2001
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 27.01.2000 takes the place of the publication of the European patent application.
	[2001/19]
	Type:	B1 Patent specification
	No.:	EP1097167
	Date:	25.10.2006
	Language:	EN
	[2006/43]
	Type:	B2 New European patent specification
	No.:	EP1097167
	Date:	12.12.2018
	Language:	EN
	[2018/50]
Search report(s)	International search report - published on:	EP	09.11.2000
Classification	IPC:	C07K14/475, C12N15/11, C12N15/63, C12N5/16, A61K38/18, G01N33/53, G01N33/68, C12Q1/68	[2001/19]
	CPC:	C07K14/475 (EP,KR,US); G01N33/53 (KR); A61K38/00 (EP,KR,US); A61P1/00 (EP); A61P1/04 (EP); A61P1/08 (EP); (+) A61P1/10 (EP); A61P1/12 (EP); A61P21/00 (EP); A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP); A61P25/14 (EP); A61P25/16 (EP); A61P25/28 (EP); A61P29/00 (EP); A61P35/00 (EP); A61P43/00 (EP); A61P9/00 (EP); G01N33/6896 (KR); A01K2217/05 (EP,KR,US); A61K2039/51 (EP,KR,US) (-)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2018/50]
Former [2001/19]	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Extension states	AL	09.05.2001
	LT	09.05.2001
	LV	09.05.2001
	MK	09.05.2001
	RO	09.05.2001
	SI	09.05.2001
Title	German:	NEUROTROPHISCHER WACHSTUMSFAKTOR	[2001/19]
	English:	NEUROTROPHIC GROWTH FACTOR	[2001/19]
	French:	FACTEUR DE CROISSANCE NEUROTROPHIQUE	[2001/19]
Biological material	This application mentions deposited biological material, check the file for details
Entry into regional phase	14.02.2001	National basic fee paid
	09.05.2001	Designation fee(s) paid
	09.05.2001	Examination fee paid
Examination procedure	18.01.2000	Request for preliminary examination filed International Preliminary Examining Authority: EP
	09.05.2001	Examination requested [2001/27]
	04.07.2003	Despatch of a communication from the examining division (Time limit: M04)
	31.10.2003	Reply to a communication from the examining division
	31.03.2004	Despatch of a communication from the examining division (Time limit: M06)
	06.08.2004	Reply to a communication from the examining division
	30.03.2005	Despatch of a communication from the examining division (Time limit: M04)
	18.04.2005	Reply to a communication from the examining division
	19.10.2005	Communication of intention to grant the patent
	28.02.2006	Fee for grant paid
	28.02.2006	Fee for publishing/printing paid
	13.03.2006	Observations by third parties
	12.04.2006	Despatch of a communication from the examining division (Time limit: M02)
	08.06.2006	Reply to a communication from the examining division
	27.07.2006	Observations by third parties
Divisional application(s)	EP05112473.3 / EP1640381
Opposition(s)	Opponent(s)	01 23.07.2007 07.11.2007 ADMISSIBLE BIOGEN IDEC INC. 14, CAMBRIDGE CENTER CAMBRIDGE MA 02142 / US Opponent's representative Dörries, Hans Ulrich df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE
		02 24.07.2007 07.11.2007 ADMISSIBLE NsGene A/S Baltorpvej 159 2750 Ballerup / DK Opponent's representative Dörries, Hans Ulrich df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE
		[2014/50]
	Former [2010/17]
	Opponent(s)	01 23.07.2007 07.11.2007 ADMISSIBLE BIOGEN INC. 14 Cambridge Center Cambridge MA 02142 / US Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 24.07.2007 07.11.2007 ADMISSIBLE NsGene A/S Baltorpvej 159 2750 Ballerup / DK Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
	Former [2008/47]
	Opponent(s)	01 23.07.2007 07.11.2007 ADMISSIBLE BIOGEN INC. 14 Cambridge Center Cambridge MA 02142 / US Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 24.07.2007 07.11.2007 ADMISSIBLE NsGene A/S Baltorpvej 159 2750 Ballerup / DK Opponent's representative Hoeiberg, Susanne Hoeiberg A/S St. Kongensgade 59 A 1264 Copenhagen K / DK
	Former [2007/42]
	Opponent(s)	01 23.07.2007 BIOGEN INC. 14 Cambridge Center Cambridge MA 02142 / US Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 24.07.2007 NsGene A/S Baltorpvej 159 2750 Ballerup / DK Opponent's representative Hoeiberg, Susanne Hoeiberg A/S St. Kongensgade 59 A 1264 Copenhagen K / DK
	10.09.2007	No. 01: Notification indicating deficiencies in the notice of opposition
	10.09.2007	No. 02: Notification indicating deficiencies in the notice of opposition
	18.09.2007	No. 02: Reply to notification indicating deficiencies in the notice of opposition
	10.10.2007	No. 01: Reply to notification indicating deficiencies in the notice of opposition
	14.11.2007	Invitation to proprietor to file observations on the notice of opposition
	23.05.2008	Reply of patent proprietor to notice(s) of opposition
	16.09.2009	Date of oral proceedings
	04.12.2009	Despatch of minutes of oral proceedings
	20.01.2016	Despatch of a communication from the opposition division (Time limit: M04)
	01.03.2016	Reply to a communication from the opposition division
	12.04.2016	Despatch of a communication from the opposition division (Time limit: M02)
	21.10.2016	Despatch of interlocutory decision in opposition
	31.10.2016	Legal effect of interlocutory decision in opposition
	20.07.2018	Despatch of communication that the patent will be maintained as amended
	29.10.2018	Fee for printing new specification paid
Appeal following opposition	03.02.2010	Appeal received No. T0334/10
	13.04.2010	Statement of grounds filed
	13.11.2014	Result of appeal procedure: maintenance in amended form
	12.11.2014	Date of oral proceedings
	01.12.2014	Minutes of the oral proceedings despatched
Fees paid	Renewal fee
	31.07.2001	Renewal fee patent year 03
	31.07.2002	Renewal fee patent year 04
	31.07.2003	Renewal fee patent year 05
	02.08.2004	Renewal fee patent year 06
	01.08.2005	Renewal fee patent year 07
	31.07.2006	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	25.10.2006
	NL	25.10.2006
	[2019/46]
Former [2019/41]	NL	25.10.2006
Former [2019/24]	NL	25.10.2006
Cited in	International search	[E]WO0001815 (NEUROSEARCH AS [DK], et al) [E] 1-6,8-12,14-38,40-45,49-51 * pages 1-4 * * pages 6-29 *;
		[A] - LIN L F ET AL, "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments].", SCIENCE, (1993 MAY 21) 260 (5111) 1130-2., XP002914283 [A] 1-6,8-12,14-26,29-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1126/science.8493557
		[A] - CREEDON D J ET AL, "Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 JUN 24) 94 (13) 7018-23., XP000882989 [A] 1-6,8-12,14-26,29-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.94.13.7018
		[A] - MILBRANDT J ET AL, "Persephin, a novel neurotrophic factor related to GDNF and neurturin.", NEURON, (1998 FEB) 20 (2) 245-53., XP000886826 [A] 1-6,8-12,14-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1016/S0896-6273(00)80453-5
		[PX] - SAARMA M ET AL, "Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).", MICROSCOPY RESEARCH AND TECHNIQUE, (1999 MAY 15-JUN 1) 45 (4-5) 292-302. REF: 83, XP000885944 [PX] 1-6,8-12,14-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8
		[PX] - BALOH R H ET AL, "Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex.", NEURON, (1998 DEC) 21 (6) 1291-302., XP000857438 [PX] 1-6,8-12,14-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1016/S0896-6273(00)80649-2
		[T] - MASURE S ET AL, "Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variants.", EUROPEAN JOURNAL OF BIOCHEMISTRY, (1999 DEC) 266 (3) 892-902., XP000882986 [T] 1-6,8-12,14-38,40-45,49-51 * the whole document * DOI: http://dx.doi.org/10.1046/j.1432-1327.1999.00925.x
	Opposition	WO0034475
		- HANSSON, P., PAIN, vol. II, no. 3, pages 1 - 8

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p